The thinking behind Lidakol trials

The thinking behind Lidakol trials

Like many biotech company executives who now realize that getting most products through the FDA won't be a slam dunk, Lidak Pharmaceuticals Inc. chairman and CEO David Katz has been thinking about how to maximize his drug's approvability since the start of clinical trials.

In designing the Phase II trials of the antiviral Lidakol against herpes, Katz said, "we were striving to be sufficiently stringent

Read the full 698 word article

How to gain access

Continue reading with a
two-week free trial.